EUVIMEDEUVIMED entdecken
Crossref

Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

Sini Vahtera, Jaana Hagström, Harri Mustonen, Topi Aulis Tervonen, Juha Klefström, Malin Sund, Caj Haglund, Hanna Seppänen

Oncology · 2025

DOI: 10.1159/000547820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Sini Vahtera und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Helsinki University and Helsinki University Hospital, Helsinki, Finland, sini.t.vahtera@helsinki.fi. Hauptthemen laut MEDLINE: Deoxycytidine, Carcinoma, Pancreatic Ductal, Serine Endopeptidases, Pancreatic Neoplasms. Die Arbeit nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepsin is a type 2 transmembrane serine protease, primarily located on the cell membrane, which can degrade the extracellular matrix and modify connections between cells and the extracellular matrix. Given these features, hepsin is thought to play a role in cancer invasion and metastasis. While studied in various other cancers, hepsin’s role in pancreatic cancer remains unexamined.

Methods

Our study included 223 patients diagnosed with pancreatic ductal adenocarcinoma. Among these, 66 received neoadjuvant therapy and these were analyzed separately. Tissue microarrays and immunohistochemistry were used to assess the expression of hepsin in pancreatic ductal adenocarcinoma tissue. Hepsin expression intensity, ranging from negative to strong, was evaluated against clinicopathological parameters, including age at surgery, sex, T-stage, N-stage, tumor grade, perivascular and perineural invasion, CA19-9 levels, ASA class, stage, and, in the neoadjuvant-treated group, response to neoadjuvant therapy.

Results

A strong hepsin expression was observed in 105 (67%) patients who did not receive neoadjuvant therapy, while 27 (42%) neoadjuvant-treated patients exhibited a strong expression. Hepsin expression did not associate with survival in either group. In the neoadjuvant-treated group, a strong positivity was, however, associated with a lower T-stage (p = 0.005) and higher N-stage (p = 0.048). Among those receiving gemcitabine-based chemotherapy, a weaker hepsin expression was associated with a better treatment response (p = 0.011).

Conclusions

A low hepsin expression following neoadjuvant therapy is associated with a better treatment response among those receiving gemcitabine-based treatment. Thus, hepsin does not appear to influence prognosis in pancreatic cancer patients, regardless of whether they received neoadjuvant therapy or not.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineCarcinoma, Pancreatic DuctalSerine EndopeptidasesPancreatic NeoplasmsHumansGemcitabineMaleFemaleNeoadjuvant TherapyMiddle AgedAgedAdultBiomarkers, TumorPrognosisAged, 80 and overAntimetabolites, Antineoplastic

Stichwörter der Autor:innen

Neoadjuvant chemotherapyPancreatic cancerPredictive factor

Substanzen

GemcitabineDeoxycytidineSerine EndopeptidaseshepsinBiomarkers, TumorAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Helsinki University and Helsinki University Hospital, Helsinki, Finland, sini.t.vahtera@helsinki.fi.
  • Cancer Cell Circuitry Laboratory, Faculty of Medicine, Translational Cancer Medicine Research Program, Research Program Unit, University of Helsinki, Helsinki, Finland, sini.t.vahtera@helsinki.fi.
  • Department of Pathology, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
  • Department of Oral Pathology and Radiology, University of Turku, Turku, Finland.
  • Department of Gastroenterological Surgery, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
  • Cancer Cell Circuitry Laboratory, Faculty of Medicine, Translational Cancer Medicine Research Program, Research Program Unit, University of Helsinki, Helsinki, Finland.

Zitieren

APA

Vahtera, S., Hagström, J., Mustonen, H., Tervonen, T. A., Klefström, J., Sund, M., Haglund, C., & Seppänen, H. (2025). Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Oncology. https://doi.org/10.1159/000547820

Vancouver

Vahtera S, Hagström J, Mustonen H, Tervonen TA, Klefström J, Sund M, et al. Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Oncology. 2025. doi:10.1159/000547820

BibTeX
@article{Vahtera2025,
  author = {Vahtera, Sini and Hagström, Jaana and Mustonen, Harri and Tervonen, Topi Aulis and Klefström, Juha and Sund, Malin and Haglund, Caj and Seppänen, Hanna},
  title = {Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000547820}
}
Kostenlos starten →